Modulus vende ativos de tecnologia de terapia celular para Ginkgo Bioworks de Boston – GeekWire

# **Revolutionary Cell Therapy Platform Sold to Ginkgo Bioworks**


—

### **Introduction**

Seattle-based cellular therapy company, Modulus Therapeutics, recently made headlines by selling its innovative cell therapy platform assets to the reputable biotech company, Ginkgo Bioworks. The terms of the acquisition remain undisclosed, but the implications of this strategic move are significant in the world of medical therapeutics.

—

### **The Breakthrough Technology**

Modulus Therapeutics has been at the forefront of genetic advancements in natural killer (NK) cells, showcasing their potential in treating autoimmune diseases. By developing a platform that harnesses the power of unique cell therapy receptors from NK and T-cells, Modulus has set the stage for more effective and safer medical treatments.

Ginkgo Bioworks, known for its trailblazing business development strategies, aims to leverage these innovative cell therapy libraries to enhance the efficacy of their future medical solutions. With a plethora of new receptor designs under their belt, Ginkgo is poised to revolutionize the landscape of medical therapies.

—

### **The Visionaries Behind the Innovation**

Modulus was co-founded by Max Darnell and bioinformatician Bryce Daines, who brought their expertise together to drive groundbreaking advancements in cell therapy. Supported by investors like Madrona Venture Group and AI2, Modulus has been a beacon of innovation in the biotech sphere.

While the acquisition by Ginkgo signifies a shift in the company’s trajectory, the collective efforts of Modulus’s team have laid a strong foundation for the future of cellular therapies. The departure of some team members post-acquisition raises questions about the company’s continued operations, but the legacy of their pioneering work remains.

—

### **Conclusion**

The acquisition of Modulus’s cell therapy platform by Ginkgo Bioworks marks a pivotal moment in the realm of medical therapeutics. By amalgamating cutting-edge technology with visionary leadership, these companies are driving transformative changes in how we approach healthcare solutions. As the legacy of Modulus lives on within Ginkgo, the future holds immense promise for the intersection of technology and medicine.